Abstract: PO0605
Association of Serum Sclerostin Levels with Mortality in Maintenance Hemodialysis Patients: An 8-Year Prospective Cohort Study
Session Information
- Vascular Disease, Nephrolithiasis, and Mineral Metabolism: Clinical
November 04, 2021 | Location: On-Demand, Virtual Only
Abstract Time: 10:00 AM - 12:00 PM
Category: Bone and Mineral Metabolism
- 402 Bone and Mineral Metabolism: Clinical
Authors
- Nakagawa, Yosuke, Tokai Daigaku, Isehara, Kanagawa, Japan
- Komaba, Hirotaka, Tokai Daigaku, Isehara, Kanagawa, Japan
- Wada, Takehiko, Tokai Daigaku, Isehara, Kanagawa, Japan
- Kakuta, Takatoshi, Tokai Daigaku Igakubu Fuzoku Hachioji Byoin, Hachioji, Tokyo, Japan
- Fukagawa, Masafumi, Tokai Daigaku, Isehara, Kanagawa, Japan
Background
Sclerostin is an osteocyte-derived inhibitor of bone formation and is increased in kidney failure. Sclerostin might be involved in the pathogenesis of vascular calcification, but few studies examined the association between sclerostin and mortality in hemodialysis patients.
Methods
We analyzed a cohort of 654 maintenance hemodialysis patients enrolled in the Tokai Dialysis Prospective Cohort Study. The primary exposure variable was the baseline serum sclerostin level, measured using a sandwich ELISA (Biomedica Medizinprodukte GmbH & Co KG). The primary outcome was 8-year all-cause mortality. Mortality risk was assessed using Cox regression models adjusted for potential confounders.
Results
aseline median (IQR) serum sclerostin level was 163 (120-215) pmol/L. Patients with higher sclerostin levels were likely to be male; have diabetes; have better nutritional status, higher hemoglobin, and lower intact PTH and bone turnover markers. No associations were observed between serum sclerostin and cardiovascular comorbidities. During a median follow-up of 7.6 years (IQR, 4.1-8.0 years), 229 of the 654 participants died. In univariate analysis, serum sclerostin levels were not associated with mortality (HR per doubling, 0.94; 95% CI, 0.76-1.17). This result was unchanged after adjustment for age, sex, dialysis vintage, diabetes, prior cardiovascular disease, body mass index, hemoglobin, albumin, and creatinine (HR per doubling, 1.07; 95% CI, 0.82-1.40).
Conclusion
Serum sclerostin levels were not associated with mortality in maintenance hemodialysis patients. Further research is required to determine the role of sclerostin in vascular calcification and cardiovascular disease in kidney failure.
Funding
- Government Support – Non-U.S.